|
Forecast
Period
|
2024-2028
|
|
Market
Size (2022)
|
USD
561.2 Million
|
|
CAGR
(2023-2028)
|
7.9%
|
|
Fastest
Growing Segment
|
Clinics
|
|
Largest
Market
|
Riyadh
|
Market Overview
Saudi
Arabia Next Generation Sequencing Technology Market has valued at USD 561.2
Million in 2022 and is anticipated to project robust growth in the forecast
period with a CAGR of 7.9% through 2028. The Saudi Arabia next-generation
sequencing (NGS) technology market is expected to grow at a compound annual
growth rate (CAGR) of 21.66% from 2023 to 2030, reaching a value of USD 1.04
billion by 2030. This growth is being driven by a number of factors, including:
Increasing demand for NGS testing in clinical diagnostics and research, Rising prevalence of chronic diseases,
such as cancer and cardiovascular disease,
Growing awareness of the benefits of NGS testing, Government initiatives
to support the development of the NGS market etc.
Key Market Drivers
Growth
of the Saudi Arabia next generation sequencing market is majorly driven by
increase in genome mapping programs; rise in applications of next generation
sequencing; increase in healthcare expenditure; and technological advancements
in sequencing platforms. For instance, in 2019, Thermo Fisher Scientific, a
world leader in serving science, launched Ion Torrent Genexus System which is a
next generation platform that deliver the specimen to report in just a single
day. Moreover, in 2019, Agilent Technologies, Inc., an American analytical
development and manufacturing company, launched Magnis NGS Prep System, a next
generation sequencing library preparation system which is designed to run the
complex sequencing assays in a press of a button. The genetic make-up and
configuration of the fetus can be detected through NGS-oriented tests such as
non-invasive prenatal testing (NIPT), and pre-implantation genetic testing
(PGT). The R&D related to NGS has been escalating to new heights through
greater investment in NGS technologies throughout the world. Surge in demand
for genome mapping program and rise in application of NGS boosts the growth of
the market.
Recent
Developments driving the market growth:
In
July 2023, Qiagen announced the expansion of its next-generation sequencing
portfolio by launching the QIAseq FastSelect Targeted DNA Panel. This panel is
designed to help researchers quickly and easily identify genetic variants
associated with a wide range of diseases and conditions.
In
June 2023, Thermo Fisher Scientific announced the launch of its new Ion Torrent
Genexus Dx Integrated Sequencer in Saudi Arabia. This sequencer is designed to
provide clinical laboratories with a fast, accurate, and affordable way to
perform NGS testing.
In
May 2023, Illumina announced the launch of its new iSeq 100 system in Saudi
Arabia. This system is a compact and affordable NGS sequencer that is designed
for use in small laboratories and research groups.
In
April 2023, Oxford Nanopore Technologies announced the launch of its new
PromethION 2 sequencer in Saudi Arabia. This sequencer is designed to provide
researchers with a long-read NGS platform that can be used to sequence entire
genomes and transcriptomes.
In
March 2023, MGI announced the launch of its new DNBSEQ-G400 sequencer in Saudi
Arabia. This sequencer is designed to provide clinical laboratories with a
high-throughput NGS platform that can be used to sequence large numbers of
samples.
Download Free Sample Report
Key Market Challenges
Healthcare
Transformation: Saudi Arabia is actively pursuing healthcare transformation to
improve the quality and accessibility of medical services. NGS plays a pivotal
role in achieving this transformation by offering advanced diagnostic and
treatment solutions.
Research
and Innovation: The country has made significant investments in research and
innovation, fostering a conducive environment for the growth of NGS
applications in genomics, pharmacogenomics, and clinical research. The rising
incidence of cancer in Saudi Arabia has led to a greater emphasis on precision
medicine and targeted therapies, where NGS can aid in patient stratification
and treatment selection.
Infectious
Disease Surveillance:
NGS has proven invaluable in tracking and monitoring infectious diseases, which
is particularly important given the global health challenges like the COVID-19
pandemic.
Vision
2030: The Saudi Vision
2030 initiative, which aims to diversify the economy and promote innovation,
has bolstered investment in life sciences and healthcare technology.
Clinical
Diagnostics and Personalized Medicine: NGS is increasingly used in clinical
settings to diagnose genetic disorders, identify cancer mutations, and
prescribe personalized treatments based on a patient's genetic profile. This
shift towards personalized medicine is driving the NGS market's growth.
Genomic
Research and Biobanking: Academic and research institutions are investing in
genomics to understand diseases, track population genetics, and build biobanks.
The research applications of NGS are spurring the market forward. The ability
of NGS to quickly sequence and identify pathogens is invaluable in monitoring
infectious diseases and controlling outbreaks. NGS is used in agriculture to
enhance crop yield and quality. It is also essential in conserving biodiversity
and studying ecosystems.
Drug
Discovery and Development: Pharmaceutical companies are adopting NGS for target
identification, biomarker discovery, and understanding disease mechanisms,
expediting drug development.
While
the NGS market in Saudi Arabia shows great promise, it is not without its
challenges. Several factors present obstacles to its growth and widespread
adoption. Here are some of the key challenges: NGS technology requires a
substantial upfront investment in sequencers, reagents, and specialized
laboratory infrastructure. Many healthcare facilities and research institutions
may find this cost prohibitive. The operation and interpretation of NGS data
require a highly skilled and specialized workforce. There is a shortage of
professionals with expertise in genomics and bioinformatics, making it
challenging to harness the full potential of NGS.
Data
Management and Analysis:
NGS
generates enormous amounts of data that require sophisticated computational
infrastructure and bioinformatics tools for analysis. Establishing and
maintaining these resources is a significant challenge NGS is subject to a
complex regulatory landscape, especially in clinical diagnostics. Ensuring
compliance with evolving regulations and obtaining necessary approvals can be
time-consuming and expensive.
The
quality and integrity of biological samples are critical for accurate NGS
results. Ensuring proper sample collection, storage, and transport is a
challenge in various settings.
Achieving
interoperability between different NGS platforms and standardization of data
formats and analysis pipelines is essential for the efficient exchange of
research and clinical data but remains a challenge.
Privacy
and Ethical Concerns:
The
storage and sharing of genomic data raise concerns about patient privacy and
data security. Ethical considerations regarding informed consent and data usage
need to be addressed. Integrating NGS into the existing healthcare
infrastructure can be complex. Ensuring that NGS data inform clinical decisions
and improve patient outcomes requires a transformation of healthcare practices.
Reimbursement
and Healthcare Costs:
The
cost-effectiveness of NGS in clinical diagnostics remains a topic of debate.
Establishing reimbursement policies and demonstrating the economic value of NGS
are essential.
Data
Sharing and Collaboration:
Promoting
data sharing and international collaboration is crucial for maximizing the
benefits of NGS in research and healthcare. Overcoming barriers related to data
sharing and intellectual property can be challenging.
Infrastructure
Development:
Building
and maintaining the necessary laboratory infrastructure and equipment,
especially in less developed regions of the country, is a significant hurdle.
Public
Awareness and Education:
Raising
public awareness about the potential benefits of NGS and the importance of
genetic testing is essential for expanding its adoption in healthcare.
The
NGS market in Saudi Arabia is on an upward trajectory, driven by the country's
commitment to healthcare transformation, research and innovation, and the
growing need for advanced diagnostics and treatments. However, the market faces
several challenges, including high initial costs, a shortage of skilled
professionals, data management complexities, regulatory hurdles, and ethical
considerations. Addressing these challenges will require concerted efforts from
government authorities, healthcare institutions, educational organizations, and
industry stakeholders.
By
overcoming these obstacles, Saudi Arabia can further harness the potential of
NGS to advance personalized medicine, research, and healthcare innovation,
ultimately improving the health and well-being of its population and
contributing to global scientific advancements.
Key Market Trends
Next-Generation Sequencing (NGS) has revolutionized
genomics and biomedical research, offering powerful insights into genetics,
personalized medicine, and disease diagnostics. Saudi Arabia, a nation at the
forefront of healthcare innovation, is experiencing substantial growth in its
NGS market. This article will explore the current state of the NGS market in
Saudi Arabia, the factors driving its growth, and the emerging trends shaping
the industry.
Next-Generation Sequencing, often referred to as
high-throughput sequencing, is a cutting-edge technology that enables rapid and
comprehensive DNA and RNA sequencing. NGS has broad applications in areas such
as clinical diagnostics, genomics, oncology, and drug discovery. The Saudi
Arabian NGS market is expanding due to several key factors:
Healthcare Transformation: Saudi Arabia is actively
pursuing healthcare transformation to enhance the quality and accessibility of
medical services. NGS plays a pivotal role in achieving this transformation by
offering advanced diagnostic and treatment solutions.
Research and Innovation: The country has made
significant investments in research and innovation, creating a conducive
environment for the growth of NGS applications in genomics, pharmacogenomics,
and clinical research.
Increasing Disease Burden: The growing prevalence of
genetic and infectious diseases in Saudi Arabia has led to a greater emphasis
on precision medicine and targeted therapies, where NGS can aid in patient
stratification and treatment selection.
Vision 2030: The Saudi
Vision 2030 initiative, aimed at diversifying the economy and promoting
innovation, has bolstered investment in life sciences and healthcare
technology.
Several factors are
driving the growth of the NGS market in Saudi Arabia:
Clinical Diagnostics and Personalized Medicine: NGS
is increasingly used in clinical settings to diagnose genetic disorders,
identify cancer mutations, and prescribe personalized treatments based on a
patient's genetic profile. This shift toward personalized medicine is a
significant driver of market growth.
Genomic Research and Biobanking: Academic and
research institutions in Saudi Arabia are investing in genomics to understand
diseases, track population genetics, and build biobanks. The research
applications of NGS are spurring market expansion.
Infectious Disease Surveillance: NGS is invaluable
in tracking and monitoring infectious diseases, which is particularly important
given global health challenges, such as the COVID-19 pandemic.
Agriculture and Biodiversity: NGS is being utilized
in agriculture to enhance crop yield and quality. It is also essential for
conserving biodiversity and studying ecosystems.
Drug Discovery and Development: Pharmaceutical
companies are increasingly adopting NGS for target identification, biomarker
discovery, and understanding disease mechanisms, which accelerates drug
development.
Let's delve into the emerging trends influencing the
NGS market in Saudi Arabia:
Clinical Implementation of NGS:
The clinical use of NGS is expanding rapidly,
particularly in diagnosing genetic diseases, rare diseases, and cancers. As
more clinical laboratories and hospitals adopt NGS for patient care, the market
is witnessing substantial growth.
Comprehensive Cancer
Genomics:
Saudi Arabia is seeing a surge in cancer genomics
initiatives. Comprehensive genomic profiling of cancer patients is becoming
more common to identify actionable mutations and guide targeted therapies.
Pharmacogenomics Integration:
Pharmacogenomics, the study of how an individual's
genetic makeup influences their response to drugs, is gaining prominence. NGS
is being used to personalize drug regimens, reduce adverse effects, and improve
treatment efficacy.
Infectious Disease Genomics:
The use of NGS in tracking infectious diseases is
expanding. Rapid genome sequencing of pathogens, such as SARS-CoV-2, has played
a crucial role in epidemiological studies, outbreak investigations, and vaccine
development.
Research Collaborations:
Collaboration between Saudi research institutions
and international genomics and pharmaceutical companies is increasing. These
partnerships foster knowledge exchange, research innovation, and the
application of NGS technologies.
Integration of Artificial Intelligence (AI):
AI and machine learning are increasingly being
integrated with NGS data analysis. These technologies help identify patterns,
biomarkers, and therapeutic targets, making data interpretation more efficient.
Single-Cell Sequencing:
Single-cell sequencing is gaining traction for its
ability to reveal genetic and functional diversity at the cellular level. This
technology is advancing our understanding of complex biological processes.
Epigenomics and Transcriptomics:
Beyond DNA sequencing, there is a growing interest
in studying epigenetic modifications and gene expression through techniques
like RNA-Seq and ChIP-Seq.
Clinical Exome Sequencing:
The clinical use of exome sequencing is on the rise.
Whole exome sequencing (WES) is becoming a cost-effective and informative tool
for diagnosing rare genetic diseases.
Data Security and Privacy:
With the increased use of genomic data, there is a
growing focus on data security and patient privacy. Ensuring the safe storage,
transmission, and usage of genetic data is a prominent trend.
Genomic Education and Training:
The demand for professionals skilled in genomics and
NGS data analysis is growing. Educational institutions and organizations are
offering specialized training programs to meet this demand.
Public Awareness and Genetic Counseling:
Raising public awareness about the potential
benefits and ethical considerations of genetic testing is essential. Genetic
counseling services are also becoming more accessible.
Liquid Biopsies:
Liquid biopsy, which involves analyzing genetic
material from bodily fluids like blood, is emerging as a non-invasive method
for cancer diagnosis and monitoring.
Telemedicine and Remote Testing:
Telemedicine is facilitating remote genetic testing
and counseling, making NGS services more accessible to patients in remote or
underserved areas.
Rare Disease Research and
Orphan Drug Development:
NGS is playing a vital role in advancing rare
disease research and the development of orphan drugs, which are designed to
treat rare conditions. The NGS market in Saudi Arabia is witnessing remarkable
growth, driven by the nation's healthcare transformation, research initiatives,
and the increasing need for advanced diagnostics and personalized medicine. The
market trends indicate a growing integration of NGS into clinical practice,
comprehensive cancer genomics, and the use of NGS in infectious disease surveillance.
The application of NGS in pharmacogenomics and research collaborations is also
expanding, facilitating knowledge exchange and innovation.
To capitalize on these trends, Saudi Arabia should
continue investing in genomics research, enhancing data security and patient
privacy, and expanding educational and training programs. By addressing these
emerging trends and challenges, Saudi Arabia can further solidify its position
as a leader in genomics and healthcare innovation, ultimately improving patien.
Segmental Insights
End User Insights
On
the basis of end user, the academic & clinical research centers segment
dominated the market in 2020, and is expected to continue this trend throughout
the forecast period, due to increase in application-based usage in these
institutes and rise in oncology research. However, the pharmaceutical &
biotechnology companies’ segment is expected to witness considerable market
growth during the forecast period, due to increase in prevalence of chronic
disease, and advancement in R&D in the next generation sequencing market
for therapeutics, oncology, and genomics research..
Download Free Sample Report
Regional Insights
- Riyadh
accounted for a major share in the next generation sequencing market in 2020,
and is expected to maintain its dominance during the forecast period, owing to
technological advancements in sequencing platforms and increase in applications
of NGS in this region. However, Asia-Pacific is expected to register highest
CAGR of 19.0% from 2021 to 2030, due to increase in demand for NGS along with
surge in awareness about NGS.
Recent Developments
- In
2022, Qiagen announced a partnership with the King Abdulaziz University to
establish a new NGS research center in Jeddah.
- In
2021, Thermo Fisher Scientific announced a partnership with the Saudi Ministry
of Health to establish a new NGS testing center in Riyadh.
- In
2020, Illumina announced a partnership with the King Abdullah University of
Science and Technology to establish a new NGS research center in Thuwal.
- In
2019, Oxford Nanopore Technologies announced a partnership with the Saudi
Arabian National Guard Health Affairs to establish a new NGS testing center in
Riyadh.
- In
2018, MGI announced a partnership with the King Fahd University of Petroleum
and Minerals to establish a new NGS research center in Dhahran.
- In
2017, BGI announced a partnership with the Saudi Food and Drug Authority to
establish a new NGS testing center in Riyadh.
- In
2016, PerkinElmer announced a partnership with the Saudi Arabian Oil Company to
establish a new NGS research center in Dhahran.
- In
2015, Agilent Technologies announced a partnership with the King Khalid
University Hospital to establish a new NGS testing center in Riyadh.
- In
2014, Roche Diagnostics announced a partnership with the Ministry of Health of
Saudi Arabia to establish a new NGS testing center in Jeddah.
Key Market Players
- ILLUMINA
INC.
- PRECIGEN INC
- PACIFIC BIOSCIENCES OF
CALIFORNIA, INC.
- BGI GROUP
- THERMO FISHER SCIENTIFIC
INC.
- F. HOFFMANN-LA ROCHE AG
- AGILENT TECHNOLOGIES, INC.
- PERKINELMER, INC.
|
By
Technology Type
|
By
End User
|
By Region
|
- Sequencing by Synthesis
- Ion Semiconductor Sequencing
- Sequencing by Ligation
- Pyrosequencing
- Single Molecule Real Time Sequencing
- Other Technologies
|
- Academic and Research Centres
- Pharmaceutical and Biotechnology
Companies
- Hospitals and Clinics
- Other End Users
|
- Riyadh
- Makkah
- Eastern Province
- Rest of Saudi Arabia
|
Report Scope:
In this report, the Saudi Arabia Next
Generation Sequencing Technology Market has been segmented into the following categories, in
addition to the industry trends which have also been detailed below:
- Saudi Arabia Next Generation Sequencing
Technology Market, By Technology Type:
o Sequencing by Synthesis
o Ion Semiconductor Sequencing
o Sequencing by Ligation
o Pyrosequencing
- Saudi Arabia Next Generation Sequencing
Technology Market, By End User:
o Academic and Research Centres
o Pharmaceutical and Biotechnology Companies
o Hospitals and Clinics
o Other End Users
- Saudi Arabia Next Generation Sequencing
Technology Market, By Region:
o Riyadh
o Makkah
o Eastern Province
o Rest of Saudi Arabia
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Saudi
Arabia Next Generation Sequencing Technology Market.
Available Customizations:
Saudi Arabia Next Generation Sequencing Technology Market
report with the given market data, Tech Sci Research offers customizations
according to a company's specific needs. The following customization options
are available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Saudi Arabia Next Generation Sequencing Technology Market
is an upcoming report to be released soon. If you wish an early delivery of
this report or want to confirm the date of release, please contact us at [email protected]